Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy

Circulation

Volumn 118, Issue 2, 2008, Pages 131-139

  Sorajja, Paul ^a,b   Valeti, Uma ^a   Nishimura, Rick A ^a   Ommen, Steve R ^a   Rihal, Charanjit S ^a   Gersh, Bernard J ^a   Hodge, David O ^b   Schaff, Hartzell V ^c   Holmes, David R ^a  

^a Division of Cardiovascular Diseases and Internal Medicine   (United States)

^b Department of Cardiovascular Surgery ^*  (United States)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Ablation; Alcohol; Cardiomyopathy; Hypertrophic; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEART SURGERY; HEART TAMPONADE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MUSCLE RESECTION; PATIENT REFERRAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TERTIARY HEALTH CARE; TREATMENT OUTCOME; AGE; CATHETER ABLATION; HEART ARRHYTHMIA; HEART VENTRICLE SEPTUM; HYPERTROPHIC CARDIOMYOPATHY; METHODOLOGY; MIDDLE AGED; MORTALITY; SURVIVAL;

ALCOHOL DERIVATIVE;

AGE FACTORS; AGED; ALCOHOLS; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; FEMALE; HEART SEPTUM; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 47649084105     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.738740     Document Type: Article

References (41)

1. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron B J. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003; 348:295-303.
2. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308-1320.
3. Nishimura RA, Ommen SR. Hypertrophic cardiomyopathy: the search for obstruction. Circulation. 2006;114:2200-2202.
4. Williams WG, Wigle ED, Rakowski H, Smallhorn J, LeBlanc J, Trusler GA. Results of surgery for hypertrophic obstructive cardiomyopathy. Circulation. 1987;76(pt 2):V-104-V-108.
5. Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM. Surgical management of hypertrophic obstructive cardiomyopathy: early and late results. J Thorac Cardiovasc Surg. 1995;110:195-208.
6. Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 1996;111:586-594.
7. McCully RB, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK. Extent of clinical improvement after surgical treatment of hypertrophic cardiomyopathy. Circulation. 1996;94:467-471.
8. Merrill WH, Friesinger GC, Graham TP Jr, Byrd BF 3rd, Drinkwater DC Jr, Christian KG, Bender HW Jr. Long-lasting improvement after septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 2000;69:1732-1736.
9. Yu EH, Omran AS, Wigle ED, Williams WG, Siu SC, Rakowski H. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol. 2000;36:2219-2225.
10. Minakata K, Dearani JA, Nishimura RA, Maron BJ, Danielson GK. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. J Thorac Cardiovasc Surg. 2004;127:481-489.
11. Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Redwick K, Siu S, Ralph-Edwards A, Rakowski H. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation. 2005;111: 2033-2041.
12. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346:211-214.
13. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, Fassbender D, Gleichmann U, Sigwart U. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation. 1997;95:2075-2081.
14. Fernandes VL, Nagueh SF, Wang W, Roberts R, Spencer WH 3rd. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: the Baylor experience. Clin Cardiol. 2005;28:124-130.
15. Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS, Sachdev B, Thaman R, McKenna WJ. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy: a comparison of clinical, hemodynamic and exercise outcomes. Eur Heart J. 2002;23:1617-1624.
16. Faber L, Seggewiss H, Welge D, Fassbender D, Schmidt HK, Gleichmann U, Horstkotte D. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur J Echocardiogr. 2004;5:347-355.
17. Qin JX, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, Bauer F, Greenberg NL, Agler DA, Drinko JM, Martin M, Tuzcu EM, Smedira NG, Lytle B, Thomas JD. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol. 2001; 38:1994-2000.
18. Van der Lee C, ten Cate FJ, Geleijnse ML, Kofflard MJ, Pedone C, van Herwerden LA, Biagini E, Vletter WB, Serruys PW. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. Circulation. 2005;112: 482-488.
19. Nagueh S, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik AJ, Spencer WH. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001; 38:1701-1706.
20. Gietzen FH, Leuner CH, Obergassel L, Strunk-Mueller C, Kuhn H. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, NYHA functional class III-IV, and outflow tract obstruction only under provocable conditions. Circulation. 2002; 106: 454-459.
21. Ralph-Edwards A, Woo A, McCrindle BW, Shapero JL, Schwartz L, Rakowski H, Wigle ED, Williams WG. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg. 2005;129: 351-358.
22. Kimmelstiel CD, Maron BJ. Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2004;109: 452-455.
23. Maron BJ. Surgery for hypertrophic obstructive cardiomyopathy: alive and quite well. Circulation. 2005;111:2016-2018.
24. Report of the World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation. 1996;93:841-842.
25. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol. 1979;43:1242-1244.
26. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, Williams WG. Hypertrophic cardiomyopathy: the importance of the site and the extent of hypertrophy: a review. Prog Cardiovasc Dis. 1985; 28:1-83.
27. Bell MR, Nishimura RA, Holmes DR Jr, Bailey KR, Schwartz RS, Vlietstra RE. Does intracoronary infusion of fluosol-DA 20% prevent left ventricular diastolic dysfunction during coronary balloon angioplasty? J Am Coll Cardiol. 1990;16:959-966.
28. Holmes DR Jr, Valeti US, Nishimura RA. Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique. Catheter Cardiovasc Interv. 2005;66:375-389.
29. Sorajja P, Nishimura RA, Ommen SR, Ackerman MJ, Tajik AJ, Gersh BJ. Utility of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy. J Am Soc Echocardiogr. 2006;19:788-795.
30. WHO Monica Project Principal Investigators. The World Health Organization MONICA project (Monitoring Trends and Determinants in Cardiovascular Disease): a major international collaboration. J Clin Epidemiol. 1988;41:105-114.
31. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:470-476.
32. Chang SM, Lakkis NM, Franklin J, Spencer WH 3rd, Nagueh SF. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation. 2004;109: 824-827.
33. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED, for the Task Force on Clinical Expert Consensus Documents, American College of Cardiology, Committee for Practice Guidelines, European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687-1713.
34. Burri H, Sigwart U. Technology insight: transcoronary ablation of septal hypertrophy. Nat Clin Pract Cardiovasc Med. 2005;2:101-107.
35. Nishimura RA, Callahan MJ, Holmes DR Jr, Gersh BJ, Driscoll DJ, Trusty JM, Danielson GK, McGoon DC. Transient atrioventricular block after open-heart surgery for congenital heart disease. Am J Cardiol. 1984;53:198-201.
36. Talreja DR, Nishimura RA, Edwards WD, Valeti US, Ommen SR, Tajik A J, Dearani JA, Schaff HV, Holmes DR Jr. Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol. 2004;44: 2329-2332.
37. El Bardissi AW, Dearani JA, Stulak JM, Nishimura RA, Ommen SR, Schaff HV. Septal myectomy after previous artery ablation. Mayo Clin Proc. 2007;82:1516-1522.
38. Nagueh SF, Buergler JM, Quinones MA, Spencer WH III, Lawrie GM. Outcome of surgical myectomy after unsuccessful alcohol septal ablation for the treatment of patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007;70:795-798.
39. Baggish AL, Smith RN, Palacios I, Vlahakes GJ, Yoerger DM, Picard MH, Lowry PA, Jang IK, Fifer MA. Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Heart. 2006;92: 1773-1778.
40. Van Dockum WG, Beek AM, ten Cate FJ, ten Berg JM, Bondarenko O, Gotte MJ, Twisk JW, Hofman MB, Visser CA, van Rossum AC. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2005; 111:2503-2508.
41. Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R, Spencer WH 3rd. Regression of left ventricular hypertrophy after non-surgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2001;103:1492-1496.